Featured Coverage

John Crowley, Chairman and CEO, Featured on CNBC

Amicus Chairman and Chief Executive Officer John Crowley says treatment for Pompe disease could be the crown jewel of the company. View video.

John Crowley on CNBC

Enrique Diloné, Senior VP of Technical Operations, Featured in pharmaVOICE Supply Chain Report

Dr. Diloné discusses the unique and complex challenges in getting a therapy to geographically dispersed rare disease patients. View article.

enrique dilone pharmaVOICE

Amicus Pauses for Pompe

We did the #PauseForPompe challenge to raise awareness for those living with Pompe disease in honor of International Pompe Day, April 15th!

pause for pompe

Amicus Hosts CabaRare

Our CabaRare showcase featured entertainers living with rare diseases in honor of Rare Disease Day 2017.

Amicus COO Bradley Campbell Featured in PharmaVOICE

Mr. Campbell discusses how engagement with rare disease advocacy groups has helped Amicus build trust with patients and families. View article.

bradley campbell pharmaVOICE

Biotechnology requires massive investment: CEO John Crowley

John Crowley, CEO of Amicus Therapeutics, discusses his biotechnology business model, as well as drugs pricing.

John Crowley on CNBC Squawk Box

Amicus Therapeutics (FOLD) CEO John Crowley 'Squawk Box' on CNBC

John Crowley on CNBC Squawk Box

Amicus Therapeutics CEO: Driving science to a cure

John Crowley, Amicus Therapeutics chairman and CEO, discusses its Fabry pill development and next generation therapy for Pompe disease, with CNBC's Jim Cramer.

John Crowley

Click Here to Read the Article

One Dad’s 14-Year Quest for Cure


Seven months ago, Megan Crowley made a gutsy decision: to undergo a radical surgery to straighten out her spine, which has been crippled by Pompe disease. Photo: Lexey Swall

Megan Crowley

Click Here to Read the Article

Click Here to View the Video